AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01130727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cocoa extract rich in polyphenols
Description: 2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols
Study NCT01130727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01130727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low polyphenol cocoa extract
Description: placebo
Study NCT02990117 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT03072914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC with RIPostC
Description: The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
Study NCT02897882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung transplant
Description: Pain evaluation
Study NCT02467608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid with HUEXC030 and RZE
Description: Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
Study NCT02467608 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HRZE
Description: the same as experimental group,without the excipient of HUEXC030 only
Study NCT04375852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of autoantibodies
Description: Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
Study NCT01068379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: criopexy
Description: he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
Study NCT01068379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser
Description: Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
Study NCT02566993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (PM01183)
Study NCT02566993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin (DOX)
Study NCT02566993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX)
Study NCT02566993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CTX)
Study NCT02566993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine (VCR)
Study NCT02566993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Study NCT06709287 — intervention group
Intervention type: OTHER
Intervention: clear aligners
Description: The investigators measured pain and chewing performance at 8 time points during the first 6 months.
Study NCT06709287 — intervention group
Intervention type: OTHER
Intervention: orthodontic metal bracket
Description: Conventional metal bracket.
Study NCT04113798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 1 Assessments
Description: Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
Study NCT04113798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 1 Assessments
Description: Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
Study NCT04113798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 2 Fear Learning
Description: Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
Study NCT04113798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 2 Fear Learning
Description: Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
Study NCT04113798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 3 Fear Extinction
Description: Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
Study NCT04113798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 3 Fear Extinction
Description: Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
Study NCT04113798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3
Study NCT04113798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Exercise
Description: Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for the full duration of 30 minutes.
Study NCT04113798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 4 Recall of Fear Extinction
Description: During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur \~24 hours following Day 3, and lasts about 30 minutes.
Study NCT04113798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 4 Recall of Fear Extinction
Description: During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur \~24 hours following Day 3, and lasts about 30 minutes.
Study NCT00970658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salonsip plaster
Description: The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
Study NCT00970658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sabia plaster
Description: The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
Study NCT02190981 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound for Small Bowel Obstruction
Description: Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
Study NCT02701257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPhone bionic pancreas
Description: An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
Study NCT02701257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet bionic pancreas
Description: An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
Study NCT02701257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeris Xerisol glucagon
Description: A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
Study NCT02701257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lilly glucagon
Description: An aqueous formulation of human glucagon with limited stability that must be changed daily
Study NCT02701257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lilly glucagon
Description: An aqueous formulation of human glucagon with limited stability that must be changed daily
Study NCT02701257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet infusion set
Description: The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
Study NCT02701257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact Detach infusion set
Description: The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
Study NCT02382744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guidance
Description: Ultrasound guidance will be used to place a saphenous nerve block
Study NCT02382744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance + nerve stimulation
Description: Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
Study NCT03743506 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: With feedback
Description: To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
Study NCT03743506 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Without feedback
Description: To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
Study NCT00957242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
Study NCT04243616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)
Study NCT04243616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)
Study NCT04243616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (not mandatory)
Description: Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)
Study NCT04243616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
Study NCT00957242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo (1mg or 2.5mg)
Study NCT04243616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
Study NCT05923450 — intervention group
Intervention type: PROCEDURE
Intervention: Colorectal Resection
Description: Radical resection of colorectal cancer
Study NCT00192036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
Study NCT00192036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80 mg/m2, IV, every 21 days x 5 cycles
Study NCT00192036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
Study NCT00868452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone + (lithium or divalproex)
Description: lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
Study NCT00868452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + (lithium or divalproex)
Description: 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
Study NCT01321840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific Autoregulation Therapy (SART)
Description: Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
Study NCT01680978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily, 6 weeks
Study NCT01680978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily, 6 weeks
Study NCT04030780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: spore-forming probiotic
Description: spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks
Study NCT04030780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar capsules administered twice daily
Study NCT02466568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
Study NCT02466568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
Study NCT02466568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM.CD40L Vaccine
Description: GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
Study NCT02405585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
Study NCT02405585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Algenpantucel-L Immunotherapy
Description: HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.
Study NCT02405585 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
Study NCT02405585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.~Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection.
Study NCT03554070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium Fiber Laser Enucleation of the Prostate
Description: Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.
Study NCT03554070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fiber Laser Urolase
Description: Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm.
Study NCT01546285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Pressure Readings on B40 Patient Monitor
Description: Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
Study NCT01029015 — intervention group
Intervention type: PROCEDURE
Intervention: cystometry
Description: recording device measuring pressures though catheters placed in bladder and rectum
Study NCT05004597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: three dimensional photography using a 3dMDHead System (3dMD, Atlanta, GA, USA)
Description: A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months.
Study NCT01044303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic Escalation
Description: Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
Study NCT03059212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: High frequency rTMS for 3 to 10 min to increase the excitability of cortex.
Study NCT03059212 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: High frequency rTMS for 3 to 10 min to increase the excitability of cortex.
Study NCT03059212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Description: A rehabilitation protocol that facilitates attention, memory, execution.
Study NCT01603758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg/day or placebo will be given for 6 weeks
Study NCT03366636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Legacy
Description: Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~* 1. Thinking about the future~* 2. Present actions to achieve future success~* 3. Safeguarding one's future~* 4. Creating a Healthy Life Plan~* 5. Navigating service systems
Study NCT01519037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet 60 MG
Description: one dose of oral cinacalcet, 60mg
Study NCT01519037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: one tablet of placebo
Study NCT00761189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
Study NCT04554797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional Hypothermia
Description: Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
Study NCT02947074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Meditation
Description: Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
Study NCT00168311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.
Study NCT00168311 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TMS
Study NCT02548312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variations of financial competing interest statements
Description: Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.